울진 바다목장 해역에 서식하는 강도다리(Platichthys stellatus)의 번식능력

황인준 ( In Joon Hwang ),이재봉 ( Jae Bong Lee ),최상준 ( Sang Jun Choi ),김슬기 ( Seol Ki Kim ),차형기 ( Hyung Kee Cha ),오택윤 ( Taeg Yun Oh ),백혜자 ( Hea Ja Baek ) 한국수산과학회 2012 한국수산과학회지 Vol.45 No.3

We investigated the reproductive capacity of starry flounder Platichthys stellatus from the Uljin (UJ) marine ranching area and compared it to that of P. stellatus from the coastal waters of Pohang (PH). In UJ, female gonadosomatic index (GSI) peaked in October (3.14±0.87) and male GSI was high in October and December. In PH, female GSI peaked in January (18.64±2.15) while male GSI began to increase in October and remained high until March. Most ovaries of UJ females were immature with perinucleus oocytes, although the testes of UJ males were ripe in January. Both the ovaries and testes of PH starry flounders were ripe from January to March. The plasma estradiol-17b (E2) levels of UJ females were highest in October (4.09±1.90ng/mL) although the testosterone (T) levels of UJ males were highest in December (3.81±0.78ng/mL) and decreased gradually until April. The 17a, 20b-dihydroxy-4-pregnen-3-one (17α20βP) levels of UJ females were not detected. The E2 levels of PH females were highest in December (36.25±33.07ng/mL) and 17a20bP levels were highest in March (5.51±0.95ng/mL). The T levels of PH males were highest in December (4.03±1.34ng/mL) and decreased gradually until October. Taken together, these results suggest that most females from UJ did not reach maturation with a spawning period that was considered to be between December and January.

한국인의 Cytochrome P450 2C19 유전형 분석

윤영란,이준호,김문경,손지홍,이상섭,김종신,이순용,차인준,신재국,Yoon, Young-Ran,Lee, Jun-Ho,Kim, Moon-Kyung,Shon, Ji-Hong,Lee, Sang-Seop,Kim, Jong-Shin,Lee, Soon-Yong,Cha, In-June,Shin, Jae-Gook 대한임상약리학회 2002 臨床藥理學會誌 Vol.10 No.1

배경 : 간 cytochrome P450 2C19 (CYP2C19) 효소군은 유전적 다형성을 나타내는 대표적인 약물대사효소의 하나로, 본 연구에서는 다수의 한국인에서 CYP2C19 유전자 변이를 분석하고, 이들 변이 allele들의 출현빈도를 타 종족에서의 결과와 비교 분석하였다. 방법 : 282 명의 건강한 한국인 피험자에서 CYP2C19 (*2와 *3) allele 변이를 polymerase chain reaction restriction fragment length polymorphism (PCR­RFLP) 방법을 이용하여 분석하였다. 결 과 : 282명의 한국인 피험자 CYP2C19*1/*1 (41.8%), CYP2C19*1/*2 (35.5%), 및 CYP2C19*1/*3 (8.5%) allele 변이를 가지는 extensive metabolizer(EM)는 총 242명으로 나타났다. 40명 (14.2%)은 CYP2C19 의 poor metabolizer(PM)로 밝혀졌는데, 이들의 allele 빈도는 CYP2C19*2/*2, CYP2C19&2/*3, 및 CYP2C19*3/*3 가 각각 8.9%, 3.9%, 1.4% 로 나타 났다. 또한, 총 564개 allele에서 각 allele의 출현빈도는 CYP2C19*1, CYP2C19*2, 및 CYP2C19*3가 각각 63.8%, 28.6% 및 7.6%로 나타났다. 결 론 : 한국인의 CYP2C19 PM 유전형의 빈도는 중국인, 일본인 등의 동아시아인보다 다소 낮았으나, 이는 서양인에 비해서는 유의하게 높은 것으로 나타났다. Background : The cytochrome P450 2C19 (CYP2C19) is a well known microsomal oxidizing enzyme showing genetic polymorphism. We extensively evaluated the frequency distribution of the CYP2C19 allelic variants in a Korean population and compared to those of other ethnics. Methods : Genotyping of CYP2C19 (*2 and *3) was carried out in a total of 282 unrelated Korean subjects. CYP2C19 genotypes were determined using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Results : Two hundred forty two of 282 Korean subjects, carried extensive metabolizer(EM) genotypes including CYP2C19*1/*1 (41.8%), CYP2C19*1/*2 (35.5%), and CYP2C19*1/*3 (8.5%), respectively. Forty subjects (14.2%) were identified to have CYP2C19 poor metabolizer(PM) genotype, and the frequencies of CYP2C19*2/*2, CYP2C19&2/*3, and CYP2C19*3/*3 were 8.9%, 3.9%, 1.4% respectively. The allele frequencies of CYP2C19*1, CYP2C19*2, and CYP2C19*3 among 564 alleles evaluated were 63.8%, 28.6% and 7.6%, respectively. Conclusions : These results suggest that frequency of CYP2C19 PM genotypes is slightly lower than that of other East Asians including Chinese and Japanese, but significantly higher than Caucasian.

우리나라 일부 농촌지역의 모자보건 실태조사

김병성(Byung-Sung Kim),전해정(Hae-Jung Chon),차인준(In-Jun Cha) 한국농촌의학 지역보건학회 1992 농촌의학·지역보건 Vol.17 No.1

Nortriptyline 제제의 생물학적 동등성에 관한 연구

신재국,차인준,장인진,정원석,김용식,박찬웅,신상구 大韓臨床藥理學會 1993 臨床藥理學會誌 Vol.1 No.1

약물반응의 다양성과 약물유전학 : A Principle for the Personalized Pharmacotherapy

신재국,차인준 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.2

Individual variation in drug response is a major problem of clinical practice and of a drug development. These variation can range from therapeutic failure to adverse or even fatal effects of drugs in some patients. The incidence of serious and fatal adverse drug reactions (ADRs) has been reported to be 6.7% and 0.32% of hospitalized patients in USA, respectively. The risk for therapeutic failure or toxicity of a drug in an individual patient is determined by the interaction of genes and environment. Environmental factors include drug-drug interactions, patient's age, weight, renal and liver dysfunction, or other disease factors or clinical variables such as smoking and alcohol consumption. Many of these environmental factors have long been considered in determining the individualized dose regimen in conventional pharmacotherapeutics. However, inherited individual variability of drug responses has been left as a so called "idiosyncrasy" that are not predictable by physicians. Recently, the rapid development of pharmacogenetics/pharmacogenomics provide us extensive informations regarding on the genetic background on the wide inter-individual variation of drug responses, which is expected to lead to the era of personalized pharmacotherapy. Pharmacogenetics is a science that is interesting to the inherited variants of genes related to pharmacokinetics (drug metabolizing enzymes, drug transporters etc.) and pharmacodynamics (receptor, ion channel, target enzyme etc.), which are associated to the susceptibility of an individual to the higher risk of ADR or therapeutic failure. This review addresses the role of pharmacogenetics/pharmacogenomics in relation to wide interindividual variation of drug responses and to the possible contribution to the prediction of personalized pharmacotherapy.

임상시험의 개요

신재국,차인준 인제대학교 백병원 2002 仁濟醫學 Vol.23 No.5

Clinical trial has been extensively applied not only in drug development but for the academic researches in biomedical field. Since this is an experimental research in human subjects, the highest level of ethical and scientific requirements should be asked to the investigators and their processing. Therefore, it is not surprising that clinical trial in drug development is strictly controlled by the ethical committee(institutional review board, IRB) and governmental regulations. Good clinical practice(GCP) has been developed as a guideline to keep the ethical and scientific requirements of clinica??trial. Unreliable data obtained from non-scientific approach can not be used for the best application of drugs or medical devices in to patients, which is not ethical in terms of their unnecessary exposure in human subjects. The most ideal type of clinical trial includes prospective, randomized. controlled and double-blinded approach. This short review introduces some of the important concepts in clinical trial, especially in the design and preparation of protocol.

고속 액체 크로마토그래피(HPLC)를 이용한 혈청 Selenium(IV)의 정량분석에 관한 연구

이덕재,차인준,노정희 인제대학교 1990 仁濟醫學 Vol.11 No.3

Selenium을 Se(IV)과 선택적으로 반응하는 d-penicillamine과 반응시켜 d-penicillamine selenotrisulfide(Pen-S-Se-S Pen)을 만든 다음 7-chloro-4nitrobenz-2-oxa-1, 3-diazole과 결합시켜 형광물질을 만들어 분석하였다. Se(IV) 유도체를 형광 검출기를 사용하여 역상크로마토그래피로 분리 정량하였으며, 10ppb의 감도하에 Se(IV)는 50-200ppb에서 직선성을 나타내었다(r=0.991). 따라서 이러한 분석 방법을 사용하여 환경 공해 연구 및 생체 내에서 필수적인 미량 금속으로 알려진 Se(IV)의 정량 등 임상연구에 기초 연구 자료로 제공할 수 있을 것으로 생각된다. Selenium (IV) reacts selectively with d-penicillamine (Pen) to produce stable d-penicillamine selenotrisulfide (Pen-S-Se-S-Pen) and subsequent derivatization to fluorophore by reaction with 7-Chlor-4-nitrobenz-2-oxa-1.3-diazale. The fluorophore was separated by reversed-phase HPLC and Selenium content was determined by fluormetric detection. The calibration plots showed a linear relationship (r=0991) in the range 50-200 ppb of Selenium(IV) with a detection limit of 10 ppb(Signal to noise ratio(S/N>2)). The method could determine total content of Selenium in biological and environmental samples after digestion of the samples and reduction of Selenium(VI) to Selenium(IV).

만성 신부전 환자에서 혈액투석에 의한 Isoniazid의 제거

신재국,차인준,장인진,신상구,김윤구,한진석,김성권 大韓臨床藥理學會 1994 臨床藥理學會誌 Vol.2 No.2

Prednisolone과 Prednisone의 임상약동학적 평가

신재국,윤영란,차인준,이경훈,장인진,신상구,박찬웅 大韓臨床藥理學會 1994 臨床藥理學會誌 Vol.2 No.1

EPTC계 농약을 투여한 흰쥐에 Allidochlor를 병용 투여함으로써 간장 내 Glutathione 농도에 미치는 효과

이덕재,노정희,차인준,이인 인제대학교 1992 仁濟醫學 Vol.13 No.3

Allidochlor를 EPTC계 농약과 함께 투여하면서 흰쥐 간독성에 미치는 효과를 관찰하였다. EPTC계 농약을 투여한 흰쥐에서의 간장내 환원형 glutathione과 산화형 glutathione의 농도를 측정함으로서 간독성에 미치는 효과를 보았다. EPTC계 농약만 투여하였을 때 GSH의 농도는 약 5%의 증가를 보였으며, Allidochlor를 병용 투여하였을 때는 약 15%의 농도증가를 보여 흰쥐에서의 EPTC계 농약에 대한 Allidochlor의 해독효과가 있음을 알 수 있었다. Rats were given Allidochlor and EPTC-herbicides(0.5 and 1.0 mg/day) and GSH level in liver were measured at 5, 10, 15, 15, 20 days. The GSSG levels were not significantly changed in control, EPTC, and Allidochlor group. The GSH level was more increased(15%) in Allidochlor group than in control group.